Chris Mirabelli, Ph.D.
Chairman of the Board
Chris Mirabelli has served as the Chairman of Leap’s board of directors since 2016 and as President & CEO from 2011 to March 2020. He has been a managing director of HealthCare Ventures LLC since 2000. From December 1999 to May 2000, Chris served as President of Pharmaceutical Research and Development and as a member of the board of directors of Millennium Pharmaceuticals, following its merger with LeukoSite, where he had been serving as President, Chief Executive Officer and Chairman of the board of directors since 1993.
He was a co-founder of Ionis Pharmaceuticals (NASDAQ: IONS), where he held several positions including SVP of Research, from 1989 until 1993. Chris started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline Plc) R&D Division. He currently serves on the Dana-Farber Cancer Institute-Business Development Council, the Scripps Research Board of Overseers, and Longview Ventures Investment Committee. Chris is a member of the Fredonia College Foundation board of Directors.
He received his Ph.D. in molecular pharmacology from Baylor College of Medicine and his BS in biology from the State University of New York at Fredonia.
Chief Operating Officer
Gus Lawlor has served as Leap’s Chief Operating Officer since 2011 and has been a managing director of HealthCare Ventures LLC since 2000. He was previously Chief Operating Officer of LeukoSite, a HealthCare Ventures company. Before joining LeukoSite, he was Chief Financial Officer and VP of Corporate Development for Alpha-Beta Technology. He was also previously Chief Financial Officer and VP, Business Development, at BioSurface Technologies, a biofilm company.
He received his BA from the University of New Hampshire and his MBA from Yale University.
President & CEO
Doug Onsi has served as Leap’s Chief Financial Officer, Treasurer and Secretary since 2011 and became the President & CEO in April of 2020. He has been at HealthCare Ventures since 2007, including serving as a managing director since 2009 and the chief executive officer of Tensha Therapeutics, Inc. which was sold to Roche Holdings, Inc. He was previously at Genzyme Corporation, where he served in roles as VP, Campath Product Operations and Portfolio Management, Oncology and as VP, Business Development.
Doug received his JD from the University of Michigan Law School and his BS in biological sciences from Cornell University.
Cyndi Sirard, M.D.
Chief Medical Officer
Cyndi Sirard has served as VP of Clinical Development at Leap Therapeutics since 2011 and became the Chief Medical Officer in April of 2020. She has more than 15 years of global clinical development experience including optimization of strategic development and oversight of scientific, commercial and financial objectives for clinical programs in oncology, hematology and transplantation. Prior to joining Leap, she served in clinical development and team leadership roles with Sanofi Oncology, Genzyme Corporation, and Parexel International.
Cyndi received her MD from Chicago Medical School. She is a board certified Medical Oncologist with internal medicine and hematology/oncology training at Harvard Medical School at Beth Israel Deaconess Medical Center in Boston, Massachusetts.
Chief Manufacturing Officer
Mark O’Mahony has been VP of CMC at Leap since 2011 and became the Chief Manufacturing Officer in April of 2020. Before this, he was VP of Process Development, Manufacturing, and Quality Control at Tolerx where he led CMC operations from the company’s inception through partnerships with Genentech and GSK, and to pre-commercialization of the Otelixizumab® anti-CD3 monoclonal antibody. Prior to Tolerx, Mark worked at LeukoSite and Millennium Pharmaceuticals where he played an integral role in the approval and worldwide commercialization of the Campath® anti-CD52 monoclonal antibody.
Mark received his MBA from Boston University and a BSc in Biotechnology from Dublin City University, Ireland.
Walter Newman, Ph.D.
Senior Research Fellow
Walter Newman has served as Leap's lead scientist since 2011. Prior to his role here, he led drug discovery at LeukoSite and Critical Therapeutics where he helped bring multiple antibody and small molecule candidates to the market, including two approved monoclonal therapeutics (alemtuzumab and vedolizumab). He was also the founding CSO at Proteostasis Therapeutics and held senior roles in drug discovery at both Ortho Pharmaceuticals and Otsuka America Pharmaceuticals.
Walter is a graduate of Columbia University’s undergraduate and graduate programs with a degree in Immunology and he has co-authored more than eighty scientific articles in peer-reviewed journals.
Jay Baum, Ph.D.
Vice President and Head of Translational Medicine
Jason (Jay) Baum joined Leap in August 2020 as Vice President and Head of Translational Medicine.
Prior to Leap, he served as Executive Director and Precision Medicine Leader at Novartis, where he was accountable for the biomarker and diagnostic efforts across the Lung Cancer and General Medicine portfolios. This included approval of a companion diagnostic for the ALK inhibitor Zykadia®. Before Novartis, Jay was Head of Biomarkers and Diagnostics at Merrimack Pharmaceutics, and prior to Merrimack worked at Cell Signaling Technology.
Jay received his Ph.D. in Molecular Biology, Cell Biology and Biochemistry from Boston University and his
BA from Colgate University